Complex interrelationship and therapeutic advances in diabetic patients with atrial fibrillation

doi:10.4330/wjc.v17.i12.114575

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=34

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=14

Publishing Process of This Article

Item

Count

Browse

Download

Sum=1

Dec 26, 2025 (publication date) through Dec 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Dec 26, 2025; 17(12): 114575
Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.114575

Open in New Tab Full Size Figure Download Figure

Figure 1 Main mechanisms of atrial fibrillation in patients with diabetes. Diabetes mellitus increases atrial fibrillation risk through multiple interconnected pathways, including inflammation, oxidative stress, atrial structural and electrical remodeling, accumulation of advanced glycation end products and autonomic dysfunction. These processes involve cytokine elevation, ion channel and calcium-handling abnormalities, reactive oxygen species release and cardiac autonomic neuropathy, ultimately promoting atrial arrhythmogenesis. NLRP3: NOD-like receptor pyrin domain containing the 3; ROS: Reactive oxygen species.

Citation: Karanikola AE, Tsiachris D, Argyriou N, Botis M, Pamporis K, Xydis P, Fragoulis C, Kordalis A, Tsioufis K. Complex interrelationship and therapeutic advances in diabetic patients with atrial fibrillation. World J Cardiol 2025; 17(12): 114575
URL: https://www.wjgnet.com/1949-8462/full/v17/i12/114575.htm
DOI: https://dx.doi.org/10.4330/wjc.v17.i12.114575